Isolagen Therapy in Phase II/III Acne Scar Study
Isolagen(TM), Inc. announced today that all injections have been completed in the Phase II/III Study IT-A-008 investigating Isolagen Therapy(TM) for the treatment of moderate to severe facial acne scars. Further, approximately half of all of the study participants have completed the final observation visit. Isolagen anticipates the acne study will conclude in the first quarter of 2009.
“The second half of 2008 has been very productive for Isolagen as we continue to deliver on our clinical milestones on time and with positive results,” said Declan Daly, Chief Executive Officer of Isolagen. “We previously announced positive top-line results from our pivotal Phase III wrinkle study and positive results from our open label Phase II study of the full face. We are very excited that our acne program is progressing on time and we believe the dermatology community will be very interested in this data early next year because of the unmet need for a minimally invasive acne scar treatment. Our current priority is to gain additional funding and secure a strategic partner to help us deliver on the exciting clinical promise of the Isolagen therapy in all of these areas.”
About the Isolagen Process(TM) and Isolagen Therapy(TM)
The Isolagen Process(TM) is an innovative cellular processing system which creates a natural, living cell therapy. By multiplying a patient’s own collagen-producing cells or fibroblasts into tens of millions of new cells, a personalized treatment is created which is then returned to the patient’s skin. This treatment, known as the Isolagen Therapy(TM), is designed to improve skin damage caused by the normal effects of aging, sun damage, acne and burns.
Related Posts:
If you enjoyed this post, please consider leaving a comment, subscribe to the feed and get future articles delivered to your feed reader or follow us on Twitter.
Comments
No comments yet.
Leave a comment